Suspend recruitment for Oxford COVID-19 vaccine trials: DCGI tells Serum Institute of India
https://ift.tt/3iq9TE3
The Drugs Controller General of India (DCGI) has directed the Serum Institute of India to suspend till further orders new recruitment in phase 2 and 3 clinical trials of the Oxford COVID-19 vaccine candidate in the backdrop of pharma giant AstraZeneca pausing the trials in other countries. In order, a copy of, DCGI Dr. VG Somani on Friday also directed the Serum Institute of India (SII) to increase the safety monitoring of the subjects already vaccinated as part of the trial, and submit the plan and report.
The Drugs Controller General of India (DCGI) has directed the Serum Institute of India to suspend till further orders new recruitment in phase 2 and 3 clinical trials of the Oxford COVID-19 vaccine candidate in the backdrop of pharma giant AstraZeneca pausing the trials in other countries. In order, a copy of, DCGI Dr. VG Somani on Friday also directed the Serum Institute of India (SII) to increase the safety monitoring of the subjects already vaccinated as part of the trial, and submit the plan and report.
No comments